Welcome to our dedicated page for Vir Biotechnology news (Ticker: VIR), a resource for investors and traders seeking the latest updates and insights on Vir Biotechnology stock.
Vir Biotechnology, Inc. (Nasdaq: VIR) is a clinical-stage biopharmaceutical company developing immune-based medicines for serious infectious diseases and cancer, and its news flow reflects active clinical and corporate development. Company announcements highlight progress in chronic hepatitis delta (CHD), where Vir Biotechnology is advancing a combination of tobevibart, an investigational broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting siRNA, through the ECLIPSE registrational program.
News updates frequently cover clinical data readouts and milestones, such as Phase 2 SOLSTICE trial results in CHD showing rates of undetectable hepatitis delta virus RNA and safety findings for the tobevibart and elebsiran combination. Additional releases describe enrollment status and timelines for the ECLIPSE 1, 2 and 3 trials, which are designed to provide efficacy and safety data for potential regulatory submissions and to support access and reimbursement in key markets.
Vir Biotechnology also issues news on its oncology portfolio of PRO-XTEN dual-masked T-cell engagers, including VIR-5500 in metastatic castration-resistant prostate cancer, VIR-5818 in HER2-expressing tumors and VIR-5525 in EGFR-expressing solid tumors. These updates may include first-patient-dosed announcements, Phase 1 dose escalation progress, and plans to present safety and efficacy data at scientific meetings.
Corporate and financial communications, such as quarterly results, conference presentations and licensing agreements, also feature prominently. For example, the company has reported on a license agreement with Norgine for CHD commercial rights in Europe, Australia and New Zealand and has provided guidance on its cash runway. Investors and followers of VIR news can use this page to monitor clinical milestones, regulatory-related updates, partnering activity and financial disclosures as the company advances its infectious disease and oncology programs.
Vir Biotechnology (Nasdaq: VIR) said management will participate in three investor conferences in March 2026: TD Cowen (fireside chat Mar 2, 3:10 p.m. ET), Leerink Partners (fireside chat Mar 10, 1:40 p.m. ET), and Barclays (one-on-one meetings Mar 12).
Live webcasts of the fireside chats will be available at the company investor website and archived for 30 days.
Summary not available.
Vir Biotechnology (Nasdaq: VIR) announced a proposed underwritten public offering of $200,000,000 of common stock, with a 30-day underwriter option to purchase up to an additional $30,000,000 of shares. All shares will be offered by Vir and the offering is subject to market conditions and SEC filings.
Goldman Sachs, Leerink Partners, Evercore ISI and Barclays are book-running managers. The shares are being offered under an automatically effective Form S-3 registration filed November 3, 2023.
Vir Biotechnology (Nasdaq: VIR) reported Q4 and full-year 2025 results and provided a corporate update on Feb 23, 2026. Key developments include a global collaboration with Astellas for PSMA-targeted TCE VIR-5500, updated Phase 1 VIR-5500 data showing favorable safety and anti-tumor activity, and $781.6 million in cash and investments as of Dec 31, 2025.
Pipeline and commercial moves include a Norgine license for tobevibart+elebsiran in select regions and upcoming Phase 3 plans for VIR-5500 in 2027.
Vir Biotechnology (Nasdaq: VIR) reported updated Phase 1 dose-escalation results for VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager in metastatic castration-resistant prostate cancer (mCRPC).
In 58 monotherapy patients there were no dose-limiting toxicities, manageable Grade ≥3 treatment-related adverse events in 12% (7/58), dose-dependent anti-tumor activity in ≥3,000 µg/kg cohorts (PSA50 82%, PSA90 53%) and RECIST objective responses of 45% (5/11); registrational trial planned for 2027.
Vir Biotechnology (Nasdaq: VIR) and Astellas (TSE: 4503) entered a global collaboration to co-develop and co-commercialize VIR-5500, a PSMA-targeting PRO-XTEN dual-masked T-cell engager for prostate cancer.
Vir will receive $335M upfront/near-term, share U.S. profits 50/50, and may receive up to $1.37B additional milestones; Astellas leads U.S. commercialization and holds ex-U.S. exclusive rights. Global development costs split 60/40 (Astellas/Vir). Closing is subject to customary conditions including HSR clearance.
Vir Biotechnology (Nasdaq: VIR) will host a conference call on Monday, February 23, 2026 at 5:30 p.m. ET / 2:30 p.m. PT to provide a corporate update and discuss fourth-quarter and full-year financial results for the period ended December 31, 2025.
According to the company, the call can be accessed via the Events & Presentations page on Vir Biotechnology's website.
Vir Biotechnology (Nasdaq: VIR) reported positive Phase 2 SOLSTICE results in chronic hepatitis delta showing undetectable HDV RNA (TND) in 88% of combination tobevibart + elebsiran participants evaluated at Week 96 versus 46% with antibody monotherapy at Week 96. No treatment-related Grade ≥3 adverse events were observed in the combination arm. The registrational ECLIPSE program is fully enrolled (ECLIPSE 1 and 3) with ECLIPSE 1 topline expected in Q4 2026 and ECLIPSE 2/3 toplines in Q1 2027. Vir will present Phase 1 VIR-5500 data at ASCO GU 2026. Year-end cash and investments were ~$781M, with runway into Q4 2027 after the Norgine licensing agreement.
Vir Biotechnology (NASDAQ: VIR) announced that CEO Marianne De Backer will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 3:45 p.m. PT in San Francisco.
A live webcast will be available under Events & Presentations in the company's Investors section and the webcast will be archived for 30 days.
Vir Biotechnology (NASDAQ: VIR) granted Norgine an exclusive commercial license for the combination of tobevibart + elebsiran to treat chronic hepatitis delta in Europe, Australia and New Zealand.
Key terms: an initial reimbursement payment of EUR 55 million, up to EUR 495 million in milestones, tiered mid‑teen to high‑twenties percent royalties, and shared ECLIPSE program costs with Norgine funding ~25% of go‑forward external costs. Vir retains U.S. and other non‑Greater China rights.
Corporate and clinical updates: ECLIPSE 3 enrollment completed; Vir expects existing cash, cash equivalents and investments to extend into Q4 2027 under the current plan. Prior Phase 2 SOLSTICE data showed 66% (21/32) achieved HDV RNA target not detected with the combination and no grade 3+ treatment‑related adverse events.